GENE ONLINE|News &
Opinion
Blog

2023-07-11| R&D

Revolutionary Sequencing Technique for Cancer Signature Detection

by GeneOnline
Share To

Researchers from the Perelman School of Medicine at the University of Pennsylvania developed a new sequencing technique called Direct Methylation Sequencing (DM-Seq). This pioneering technique has the capability to directly identify modified cytosines, whose abnormal patterns are considered cancer signatures.   

Related Article: Moderna’s Personalized Cancer Therapy: The New Transformative Approach to Oncology 

Direct Methylation Sequencing’s Potential in Epigenetic Sequencing  

5-methylcytosine (5mC) is considered the most important epigenetic marker in mammalian genomes. Epigenetics studies the reversible changes to your genome caused by your environment and behavior. 5mC modifications regulate transcription by turning genes off, which means that an excessive amount of 5mCs or a lack of them leads to unusual gene expression. 

Their study, published earlier this month in Nature Chemical Biology, introduces a new sequencing technique, Direct Methylation Sequencing Technique (DM-Seq). DM-Seq uses engineered DNA-modifying enzymes to map 5-methylcytosine modifications; the two enzymes utilized are a DNA methyltransferase and a DNA transferase. The team also showed that DM-Seq is able to outperform bisulfite sequencing (BS-Seq), a well established method used to detect cytosine methylation. 

Unlike previously utilized methods, DM-Seq requires only a small amount of DNA as a sample, which is one of the main limitations of current techniques. Another important difference is that the DNA isn’t damaged, as is the case with BS-Seq. But most importantly, it is capable of differentiating between two cytosine modifications that are commonly mistaken: 5-methylcytosine and 5-hydroxymethylcytosine. This new technique has the potential to be used for the study of cell types that are difficult to characterize and to advance the use of epigenetic sequencing in cancer prognosis.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Bayer and Hurdle Develop Saliva-Based Biomarker for Chronic Inflammation Linked to Aging
2025-03-17
Researchers Work on Portable Blood Test for Colon Cancer Detection
2025-03-14
Cancerous Breast Tissue Glows in New AI-Enhanced MRI Images
2025-02-24
LATEST
CRISPR Makes History with First One-of-a-Kind Gene Therapy for Infant
2025-05-16
VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025
2025-05-15
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
Health Secretary Kennedy Retracts Parts of Agency Reorganization Plan During Combative Congressional Hearing
2025-05-14
EVENT
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top